28 completed, 9 unknown, 5 terminated, 3 active not recruiting. 51 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 51 | Completed 28, Unknown 9, Terminated 5, Active not recruiting 3, Not yet recruiting 3, Recruiting 2, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B GST-HG141 - Chronic Hepatitis b | Phase 3 | Not yet recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 576 | 2026-06-26 | 2026-05-14 |
| A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B AZVUDINE, TAF, IFNα-2a - Chronic Hepatitis B, Azvudine | Phase 3 | Recruiting | Zhigang Ren | 120 | 2025-09-01 | 2025-12-29 |
| Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) AHB-137, Placebo, NA therapy - Chronic Hepatitis B | Phase 3 | Active not recruiting | Ausper Biopharma Co., Ltd. | 577 | 2025-08-12 | 2026-05-04 |
| A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB ZM-H1505R 100mg, ZM-H1505R Placebo, NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Shanghai Zhimeng Biopharma, Inc. | 1300 | 2025-08-01 | 2025-08-03 |
| To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment GST-HG141, GST-HG141 Placebo - Chronic Hepatitis b | Phase 3 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 526 | 2025-07-24 | 2026-01-23 |
| A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B HTS 20mg, HTS 30mg, HTS 40mg - Chronic Hepatitis B | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 1444 | 2025-07-01 | 2025-10-02 |
| Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Bepirovirsen, Placebo - Chronic Hepatitis B, Hepatitis B, Chronic | Phase 3 | Completed | GlaxoSmithKline | 981 | 2022-12-07 | 2026-07-08 |
| Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Bepirovirsen, Placebo - Chronic Hepatitis B, Hepatitis B, Chronic | Phase 3 | Completed | GlaxoSmithKline | 857 | 2022-12-06 | 2026-07-08 |
| Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet, Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate - Chronic Hepatitis b | Phase 3 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 900 | 2020-09-01 | 2020-09-10 |
| A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B Peginterferon alfa-2b injection, TDF - Chronic Hepatitis B | Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 475 | 2019-12-04 | 2024-03-05 |
| Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed TAF, TDF, TAF Placebo - Chronic Hepatitis B | Phase 3 | Completed | Gilead Sciences | 490 | 2016-12-29 | 2020-09-14 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet CKD-390, viread - Chronic Hepatitis B | Phase 3 | Unknown | Chong Kun Dang Pharmaceutical | 158 | 2016-04-01 | 2016-06-21 |
| Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues Besifovir 150mg, Tenofovir 300mg - Chronic Hepatitis B | Phase 3 | Completed | IlDong Pharmaceutical Co Ltd | 146 | 2015-07-01 | 2023-02-21 |
| Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B ABX203 therapeutic Hepatitis B vaccine treatment arm - Chronic Hepatitis B | Phase 2 / Phase 3 | Completed | Abivax S.A. | 261 | 2014-12-01 | 2017-01-24 |
| Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection Telbivudine, Placebo - Chronic Hepatitis B | Phase 3 | Terminated | Novartis Pharmaceuticals | 53 | 2014-10-31 | 2019-09-10 |
| Phase 3 and Extensional Study of Besifovir besifovir 150mg, tenofovir 300mg - Chronic Hepatitis B | Phase 3 | Unknown | IlDong Pharmaceutical Co Ltd | 197 | 2013-10-01 | 2020-01-27 |
| HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance PEG-interferon-Alfa-2A, Nucleosides - Chronic Hepatitis B | Phase 3 | Unknown | Pusan National University Hospital | 144 | 2013-05-01 | 2014-11-04 |
| Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Ypeginterferon alfa-2b, Pegasys - Chronic Hepatitis B | Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 820 | 2013-03-01 | 2015-08-31 |
Showing 20 of 51. Sign in to see all of them.
Hepatitis B, Chronic (51) · Hepatitis B (11) · HIV Infections (2) · Hepatitis (2) · Hepatitis, Chronic (2) · Acquired Immunodeficiency Syndrome (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Hepatocellular (1) · HIV Seropositivity (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Blood-Borne Infections (51) · Chronic Disease (51) · Communicable Diseases (51) · DNA Virus Infections (51) · Digestive System Diseases (51) · Disease Attributes (51) · Hepadnaviridae Infections (51) · Hepatitis, Viral, Human (51) · Infections (51) · Liver Diseases (51) · Pathologic Processes (51) · Pathological Conditions, Signs and Symptoms (51) · Virus Diseases (51) · Hepatitis (49) · Hepatitis, Chronic (49)
Tenofovir (12) · Telbivudine (8) · entecavir (8) · adefovir dipivoxil (7) · Lamivudine (6) · peginterferon alfa-2a (6) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (2) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (2) · adefovir (2) · peginterferon alfa-2b (2) · Glycyrrhizic Acid (1) · Interferon alpha-2 (1) · Nucleosides (1) · Ribavirin (1) · Saline Solution, Hypertonic (1)
Gilead Sciences (6) · Bristol-Myers Squibb (5) · GlaxoSmithKline (5) · Novartis (4) · Novartis Pharmaceuticals (3) · Fujian Akeylink Biotechnology Co., Ltd. (2) · IlDong Pharmaceutical Co Ltd (2) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Xiamen Amoytop Biotech Co., Ltd. (2) · ANRS, Emerging Infectious Diseases (1) · Abivax S.A. (1) · Ausper Biopharma Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chong Kun Dang Pharmaceutical (1) · Clinical Research Organization, Dhaka, Bangladesh (1)
China (19) · United States (18) · South Korea (16) · France (10) · Canada (9) · Germany (9) · Taiwan (9) · United Kingdom (9) · Australia (8) · Italy (8) · Poland (8) · Spain (8) · Turkey (Türkiye) (8) · New Zealand (7) · Thailand (7)
Byung Seok Lee, M.D., Ph.D. (1) · Chun-Ying Wu, MD, PhD, MPH (1) · Dong Joon Kim, M.D., Ph.D. (1) · Guiqiang Wang, Ph.D (1) · Guoping Yang (1) · Hong Soo Kim, M.D., Ph.D. (1) · Hyung Joon Yim, M.D., Ph.D. (1) · Jae-Youn Cheong, M.D., Ph.D. (1)
PMID 19052126, PMID 20955704, PMID 23234725, PMID 23364953, PMID 23939953, PMID 25179493, PMID 25277773, PMID 25532501, PMID 25788199, PMID 25987775, PMID 27658343, PMID 28215615, PMID 30795958, PMID 31136052, PMID 42206582, PMID 16525137, PMID 16525138, PMID 17909201, PMID 18080339, PMID 18094378, PMID 19345439, PMID 20028815, PMID 23234302, PMID 24431895, PMID 25046847, PMID 27534671, PMID 28404133, PMID 30133478, PMID 30448598, PMID 32087795, PMID 32355123, PMID 33437904, PMID 33493393, PMID 35867702, PMID 38473248, PMID 39425534, PMID 41051280
2004 (2), 2009 (1), 2016 (1)